Our Press Releases | Association for Accessible Medicines

AAM Statement on House Energy & Commerce Passage of the CREATES Act

Apr 3, 2019 | Rachel Schwartz

AAM Statement on House Energy & Commerce Passage of the CREATES Act

Responding to the CY 2020 MA Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter

Apr 1, 2019 | Rachel Schwartz

AAM Response to CMS Final 2020 Call Letter

2019 Energy and Commerce Health Subcommittee Markup

Mar 27, 2019 | Rachel Schwartz

AAM Statement: 2019 Energy and Commerce Health Subcommittee Markup

Karin Hessler Joins AAM as Assistant General Counsel

Mar 18, 2019 | Rachel Schwartz

Karin Hessler Joins AAM as Assistant General Counsel

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Mar 11, 2019 | Rachel Schwartz

AAM Statement in Response to Administration's FY 2020 Budget Proposal

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 7, 2019 | Rachel Schwartz

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 5, 2019 | Rachel Schwartz

AAM Statement on Dr. Scott Gottlieb's Departure

AAM Statement on Avalere Report

Feb 28, 2019 | Rachel Schwartz

New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines

Jonathan Kimball Joins AAM as Vice President, Trade & International Affairs

Feb 25, 2019 | Rachel Schwartz

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

Feb 19, 2019 | Rachel Schwartz

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

AAM Welcomes the Re-introduction of the PACED Act

Feb 13, 2019 | Rachel Schwartz

AAM Welcomes Re-Introduction of the PACED Act

Pass CREATES Act - lower prescription drug prices for patients

Feb 8, 2019 | Rachel Schwartz

Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act